Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | BUB1 | O43683 | 1/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12310814 | 0.84 | HDAC6 (0.37) | HDAC6HDAC1HDAC2PDK2CA14 | |
| SCHEMBL19901069 | 0.83 | HDAC6 (0.34) | HDAC6HDAC1HDAC2PDK2CA14 | |
| SCHEMBL21894391 | 0.82 | KDM4E (0.36) | HDAC6HDAC1HDAC2PDK2CA14 | |
| SCHEMBL31732544 | 0.82 | HDAC6 (0.36) | HDAC6HDAC1HDAC2PDK2CA14 | |
| SCHEMBL4613481 | 0.81 | HDAC6 (0.36) | HDAC6HDAC1HDAC2PDK2CA14 | |
| SCHEMBL10260946 | 0.80 | HDAC6 (0.40) | HDAC6HDAC1HDAC2PDK2CA14 | |
| SCHEMBL8553597 | 0.79 | HDAC6 (0.39) | HDAC6HDAC1HDAC2PDK2CA14 | |
| SCHEMBL381146 | 0.79 | HDAC6 (0.39) | HDAC6HDAC1HDAC2PDK2CA14 | |
| SCHEMBL9354426 | 0.79 | HDAC6 (0.34) | HDAC6HDAC1HDAC2PDK2CA14 | |
| SCHEMBL1712653 | 0.79 | HDAC6 (0.37) | HDAC6HDAC1HDAC2PDK2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2023-02-09 | — | — | US | disclosed |
| WO-2020223136-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-9902712-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | HDAC6 955/4885HDAC1 767/4885HDAC2 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.